Large-scale testing (Phase 3)Active Not RecruitingNCT06305754
What this trial is testing
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC 550